

Irene Gavras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2239204/publications.pdf>

Version: 2024-02-01

108
papers

4,602
citations

109321

35
h-index

102487

66
g-index

109
all docs

109
docs citations

109
times ranked

2186
citing authors

#	ARTICLE	IF	CITATIONS
1	Blockade of platelet alpha2B-adrenergic receptors: A novel antiaggregant mechanism. International Journal of Cardiology, 2013, 168, 2561-2566.	1.7	12
2	Volume-expanded™ hypertension. Journal of Hypertension, 2012, 30, 655-659.	0.5	24
3	A novel bradykinin antagonist with improved properties. Journal of Pharmacy and Pharmacology, 2011, 43, 887-888.	2.4	21
4	Cardioprotective properties of bradykinin: role of the B2 receptor. Hypertension Research, 2010, 33, 772-777.	2.7	43
5	Cardioprotective Effects of a Selective B2 Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct. American Journal of Hypertension, 2010, 23, 562-568.	2.0	42
6	Hypertension in Transgenic Mice With Brain-Selective Overexpression of the $\hat{A}2B$ -Adrenoceptor. American Journal of Hypertension, 2009, 22, 41-45.	2.0	8
7	Angiotensin-Converting Enzyme Inhibition After Experimental Myocardial Infarct. Hypertension, 2008, 51, 1352-1357.	2.7	44
8	Pleiotropic Effects of Statins May Improve Outcomes in Atherosclerotic Renovascular Disease. American Journal of Hypertension, 2008, 21, 1163-1168.	2.0	57
9	Inhibition of the $\hat{A}1D$ -adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. Vascular Pharmacology, 2007, 46, 367-372.	2.1	5
10	A Novel Gene (Cmya3) Induced in the Heart by Angiotensin II-Dependent but not Salt-Dependent Hypertension in Mice. American Journal of Hypertension, 2006, 19, 275-281.	2.0	17
11	Long-Term Inhibition of the Central $\hat{A}2B$ -Adrenergic Receptor Gene Via Recombinant AAV-Delivered Antisense in Hypertensive Rats. American Journal of Hypertension, 2006, 19, 1135-1143.	2.0	10
12	Frequency of Coronary Artery Disease in Patients With Renal Artery Stenosis Without Clinical Manifestations of Coronary Insufficiency. American Journal of Hypertension, 2006, 19, 1125-1128.	2.0	9
13	Fixed-Drug Combinations as First-Line Treatment for Hypertension. Progress in Cardiovascular Diseases, 2006, 48, 416-425.	3.1	43
14	Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E268-E274.	3.5	41
15	The debate goes on™What is your choice?. American Journal of Cardiology, 2005, 95, 53-54.	1.6	3
16	ACE Inhibitor Trials: Effects in Hypertension. , 2005, , 386-390.		0
17	Angiotensin-converting enzyme regulates bradykinin receptor gene expression. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1814-H1820.	3.2	27
18	Age-related changes of bradykinin B1 and B2 receptors in rat heart. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H202-H205.	3.2	23

#	ARTICLE	IF	CITATIONS
19	Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. American Journal of Hypertension, 2005, 18, 18-22.	2.0	30
20	Hypertension, vasoactive peptides and coagulation factors. Journal of Hypertension, 2004, 22, 1091-1092.	0.5	7
21	Combination therapy as first-line treatment for hypertension. Current Hypertension Reports, 2004, 6, 267-272.	3.5	26
22	The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. American Journal of Hypertension, 2003, 16, 1000-1005.	2.0	3
23	Mechanisms Mediating the Vasoactive Effects of the B ₁ Receptors of Bradykinin. Hypertension, 2003, 42, 1021-1025.	2.7	30
24	Are Patients Who Develop Angioedema With ACE Inhibition at Risk of the Same Problem With AT1 Receptor Blockers?. Archives of Internal Medicine, 2003, 163, 240.	3.8	15
25	Central α 2B-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. Journal of Hypertension, 2003, 21, 961-967.	0.5	18
26	Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 323-328.	0.6	13
27	Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. American Journal of Hypertension, 2002, 15, 42-47.	2.0	3
28	Role of α 2-adrenergic receptors in hypertension. American Journal of Hypertension, 2001, 14, S171-S177.	2.0	28
29	Is ancient Greek a dead language?. Lancet, The, 2001, 358, 424.	13.7	0
30	Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1778-H1783.	3.2	39
31	The α 2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. Journal of Hypertension, 2001, 19, 2115-2124.	0.5	231
32	Vasoactive Potential of the B1Bradykinin Receptor in Normotension and Hypertension. Circulation Research, 2001, 88, 275-281.	4.5	134
33	Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 257.	1.5	5
34	Role of the B2Receptor of Bradykinin in Insulin Sensitivity. Hypertension, 2001, 38, 1355-1360.	2.7	85
35	Effects of Antisense Oligodeoxynucleotide Targeting of the α 2B-Adrenergic Receptor Messenger RNA in the Central Nervous System. Hypertension, 2001, 38, 1075-1080.	2.7	36
36	The role of ACE inhibition in heart failure. , 2001, , 71-79.		4

#	ARTICLE	IF	CITATIONS
37	Role of the postsynaptic α_2 -adrenergic receptor subtypes in catecholamine-induced vasoconstriction. <i>General Pharmacology</i> , 2000, 34, 101-106.	0.7	49
38	Role of α_2 -Adrenergic Receptor Subtypes in the Acute Hypertensive Response to Hypertonic Saline Infusion in Anephric Mice. <i>Hypertension</i> , 2000, 35, 609-613.	2.7	41
39	Role of the α_2B -Adrenergic Receptor in the Development of Salt-Induced Hypertension. <i>Hypertension</i> , 1999, 33, 14-17.	2.7	105
40	Evidence for Linkage Between Essential Hypertension and a Putative Locus on Human Chromosome 17. <i>Hypertension</i> , 1999, 34, 4-7.	2.7	81
41	The Economics of Therapeutic Advances. <i>Archives of Internal Medicine</i> , 1999, 159, 2634.	3.8	4
42	Sympathoinhibitory Function of the α_2A -Adrenergic Receptor Subtype. <i>Hypertension</i> , 1999, 34, 403-407.	2.7	75
43	Safety and Tolerability of Eprosartan. <i>Pharmacotherapy</i> , 1999, 19, 102S-107S.	2.6	13
44	The Renin-Angiotensin System and the Heart. , 1999, , 53-67.		0
45	Comparison of Spirapril, Isradipine, or Combination in Hypertensive Patients With Left Ventricular Hypertrophy Effects on LVH Regression and Arrhythmogenic Propensity. <i>American Journal of Hypertension</i> , 1998, 11, 640-648.	2.0	18
46	Renal artery clipping attenuates the progression of adriamycin nephropathy. <i>American Journal of Hypertension</i> , 1998, 11, 1124-1128.	2.0	1
47	Autosomal Dominant Orthostatic Hypotensive Disorder Maps to Chromosome 18q. <i>American Journal of Human Genetics</i> , 1998, 63, 1425-1430.	6.2	45
48	Chronic Sympathetic Suppression in the Treatment of Chronic Congestive Heart Failure. <i>Clinical and Experimental Hypertension</i> , 1998, 20, 717-731.	1.3	16
49	Role of Substance P in Blood Pressure Regulation in Salt-Dependent Experimental Hypertension. <i>Hypertension</i> , 1997, 29, 506-509.	2.7	24
50	Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure. <i>Hypertension</i> , 1997, 29, 525-530.	2.7	16
51	Role of vasopressin in essential hypertension. <i>Journal of Hypertension</i> , 1997, 15, 545-550.	0.5	93
52	Hemodynamic and Humoral Correlates in Essential Hypertension. <i>Hypertension</i> , 1997, 30, 730-734.	2.7	8
53	Models of Experimental Hypertension in Mice. <i>Hypertension</i> , 1996, 28, 1064-1069.	2.7	132
54	Modern Approaches to Initiating Antihypertensive Therapy. <i>Cardiology Clinics</i> , 1995, 13, 593-598.	2.2	2

#	ARTICLE	IF	CITATIONS
55	Augmentation of Coronary Blood Flow by Ace Inhibition: Role of Angiotensin and Bradykinin. <i>Clinical and Experimental Hypertension</i> , 1995, 17, 1059-1072.	1.3	13
56	Isradipine versus captopril in patients with essential hypertension. <i>Clinical Therapeutics</i> , 1995, 17, 648-654.	2.5	4
57	Role of Bradykinin in Insulin Sensitivity and Blood Pressure Regulation During Hyperinsulinemia. <i>Hypertension</i> , 1995, 25, 1003-1007.	2.7	37
58	Suppressing Sympathetic Activation in Congestive Heart Failure. <i>Hypertension</i> , 1995, 26, 719-724.	2.7	67
59	Cardiovascular Effects of a Specific Nonpeptide Antagonist of Substance P (NK-1) Receptor in DOCA-Salt Hypertension. <i>Hypertension</i> , 1995, 26, 1186-1189.	2.7	2
60	Age and Race Determine Vasopressin Participation in Upright Blood Pressure Control in Essential Hypertension. <i>Annals of the New York Academy of Sciences</i> , 1993, 689, 534-536.	3.8	12
61	ACE Inhibitors: A Decade of Clinical Experience. <i>Hospital Practice (1995)</i> , 1993, 28, 117-127.	1.0	4
62	Bradykinin-mediated effects of ACE inhibition. <i>Kidney International</i> , 1992, 42, 1020-1029.	5.2	112
63	Cardioprotective potential of angiotensin converting enzyme inhibitors. <i>Journal of Hypertension</i> , 1991, 9, 385-392.	0.5	45
64	Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. <i>Journal of Hypertension</i> , 1991, 9, 805-812.	0.5	19
65	Angiotensin converting enzyme inhibitors. <i>Journal of Hypertension</i> , 1991, 9, 1075.	0.5	2
66	Cardioprotective potential of angiotensin converting enzyme inhibitors. <i>Clinical Cardiology</i> , 1991, 14, 68-71.	1.8	5
67	Effect of Aging on Vasopressin, Catecholamines, and Alpha ₂ Adrenergic Receptors. <i>Journal of the American Geriatrics Society</i> , 1990, 38, 628-632.	2.6	28
68	Effects of a Novel Renin Inhibitor in Patients with Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 15, 493-500.	1.9	21
69	A new highly potent antagonist of bradykinin. <i>Peptides</i> , 1990, 11, 1041-1043.	2.4	37
70	Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. <i>Journal of Hypertension</i> , 1989, 7, 601-606.	0.5	43
71	Acute Effects of the New Angiotensin Converting Enzyme Inhibitor Cilazapril: A Pilot Study. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 660-663.	2.0	1
72	Renin-angiotensin and vasopressin in the development of salt-induced hypertension. <i>Journal of Hypertension</i> , 1988, 6, 999-1002.	0.5	4

#	ARTICLE	IF	CITATIONS
73	Role of Bradykinin in Hypertension and the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors. American Journal of the Medical Sciences, 1988, 295, 305-307.	1.1	19
74	Central Catecholamines and Alpha-Adrenoceptors in Acute Hypertension Induced by Intracerebroventricular Hypertonic Saline. Journal of Hypertension, 1987, 5, 699-704.	0.5	7
75	Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamus. Brain Research, 1987, 412, 182-184.	2.2	0
76	Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. American Journal of Medicine, 1987, 83, 20-23.	1.5	15
77	Clinical utility of angiotensin converting enzyme inhibitors in hypertension. American Journal of Medicine, 1986, 81, 28-31.	1.5	5
78	Norepinephrine applied in the paraventricular hypothalamic nucleus stimulates vasopressin release. Brain Research, 1986, 381, 322-326.	2.2	49
79	Calcium Stimulates Vasopressin Release. Journal of Hypertension, 1986, 4, 451-454.	0.5	33
80	Central Alpha-Adrenoceptors During the Development of Hypertension in Rats on High and Low Salt Intake. Journal of Hypertension, 1986, 4, 719-726.	0.5	13
81	Enalaprilat in Hypertensive Emergencies. Journal of Clinical Pharmacology, 1986, 26, 39-43.	2.0	41
82	Nifedipine in the Treatment of Essential Hypertension. Journal of Clinical Pharmacology, 1985, 25, 429-432.	2.0	8
83	Sodium Chloride-induced Partial Inhibition In Vivo Of Alpha2-Adrenoceptor Agonist Function. Journal of Hypertension, 1985, 3, 269-274.	0.5	26
84	Î±-Adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses. Brain Research, 1985, 347, 372-375.	2.2	43
85	Hypertensive response to saline microinjection in the area of the nucleus tractus solitarii of the rat. Brain Research, 1985, 343, 113-119.	2.2	18
86	Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized desoxycorticosterone-salt hypertensive rats. European Journal of Pharmacology, 1984, 102, 515-519.	3.5	4
87	Evidence for Dopaminergic Regulation of Vasopressin Release in the Anephric Rat. Journal of Hypertension, 1984, 2, 311-316.	0.5	6
88	Salt-induced hypertension in chronic renal failure: Evidence for a neurogenic mechanism. Life Sciences, 1983, 32, 733-740.	4.3	9
89	Systemic and Regional Hemodynamic Effects of Propranolol in Intact and Anephric Rats. Clinical and Experimental Hypertension, 1983, 5, 729-739.	0.3	7
90	Role of Vasoconstrictor Systems in Experimental Glucocorticoid-Hypertension in Rats. Clinical Science, 1983, 65, 255-261.	4.3	26

#	ARTICLE	IF	CITATIONS
91	Captopril and Enalapril. <i>Annals of Internal Medicine</i> , 1983, 98, 556.	3.9	35
92	Antihypertensive Therapy with MK 4211. <i>Journal of Cardiovascular Pharmacology</i> , 1982, 4, 966-972.	1.9	227
93	Prediction of sustained antihypertensive efficacy of chronic captopril therapy: Relationships to immediate blood pressure response and control plasma renin activity. <i>American Heart Journal</i> , 1982, 103, 384-390.	2.7	36
94	ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".. <i>Lancet, The</i> , 1981, 318, 543-547.	13.7	182
95	Fatal Pancytopenia Associated with the Use of Captopril. <i>Annals of Internal Medicine</i> , 1981, 94, 58.	3.9	56
96	Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An Update. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 508-516.	2.0	34
97	Effect of Pindolol on Blood Pressure, Plasma Renin Activity, and Catecholamines in Hypertensive Patients. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 79-83.	2.0	4
98	Position Paper: Vasoconstriction and Volume Factors in Renovascular Hypertension. , 1981, , 159-164.		1
99	The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension. , 1980, , 201-210.		0
100	Effect of Nadolol in Treatment of Hypertension. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 137-147.	2.0	15
101	A Comparative Study of the Effects of Oxprenolol Versus Propranolol in Essential Hypertension. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 8-14.	2.0	21
102	Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man. <i>New England Journal of Medicine</i> , 1978, 298, 991-995.	27.0	623
103	Studies on the Activity of the Sympathetic Nervous System in Essential Hypertension. <i>Journal of Human Stress</i> , 1978, 4, 22-28.	0.7	20
104	Effect of Angiotensin Converting Enzyme Inhibition on Blood Pressure, Plasma Renin Activity and Plasma Aldosterone in Essential Hypertension *. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1978, 46, 220-226.	3.6	30
105	Reciprocal Relation between Renin Dependency and Sodium Dependency in Essential Hypertension. <i>New England Journal of Medicine</i> , 1976, 295, 1278-1283.	27.0	119
106	An Angiotensin Converting-Enzyme Inhibitor to Identify and Treat Vasoconstrictor and Volume Factors in Hypertensive Patients. <i>New England Journal of Medicine</i> , 1974, 291, 817-821.	27.0	350
107	HYPOTENSIVE EFFECT OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR SQ 20,881. <i>Lancet, The</i> , 1974, 304, 353.	13.7	13
108	Volume factor in low and normal renin essential hypertension. <i>American Journal of Cardiology</i> , 1973, 32, 523-532.	1.6	192